


REMARKS

This is a full and timely response to the outstanding non-final Office action January 9, 2007. In response to the restriction requirement, Applicants respectfully elect to prosecute the claims of Group VI, corresponding to claims 16, 25-27 and 29, with without prejudice, traverse, or disclaimer. Applicants note that Group V and VI appear to recite the same restriction. It appears that the phrase "nucleic acid encoding" referenced in Group VI should be replaced with "polypeptide". It should also be noted that claims 16, 17, and 27-32 have been amended.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'C. B. Linder', written over a horizontal line.

Christopher B. Linder, Reg. No. 47,751

THOMAS, KAYDEN, HORSTEMEYER & RISLEY, L.L.P.
Suite 1750
100 Galleria Parkway N.W.
Atlanta, Georgia 30339
(770) 933-9500